A historical perspective on clonidine as an alpha-2A receptor agonist in the treatment of addictive behaviors: Focus on opioid dependence
INNOSC Theranostics and Pharmacological Sciences · 2024
DOI: 10.36922/itps.1918 ↗Kurz gefasst
Fachartikel in der Zeitschrift INNOSC Theranostics and Pharmacological Sciences, 2024. Verfasst von Mark S Gold und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
Clonidine operates through agonism at the alpha-2A receptor, a specific subtype of the alpha-2-adrenergic receptor located predominantly in the prefrontal cortex. By inhibiting the release of norepinephrine, which is responsible for withdrawal symptoms, clonidine effectively addresses withdrawal-related conditions such as anxiety, hypertension, and tachycardia. The groundbreaking work by Gold et al. demonstrated clonidine’s ability to counteract the effects of locus coeruleus stimulation, reshaping the understanding of opioid withdrawal within the field. In the 1980s, the efficacy of clonidine in facilitating the transition to long-acting injectable naltrexone was confirmed for individuals motivated to overcome opioid use disorders (OUDs), including physicians and executives. Despite challenges with compliance, naltrexone offers sustained blockade of opioid receptors, reducing the risk of overdose, intoxication, and relapse in motivated patients in recovery. The development of clonidine and naltrexone as treatment modalities for OUDs, and potentially other addictions, including behavioral ones, underscores the potential for translating neurobiological advancements from preclinical models (bench) to clinical practice (bedside), ushering in innovative approaches to addiction treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America.
- Division of Addiction Research and Education, Center for Sports, Exercise and Global Mental Health, Western University Health Sciences, Pomona, California, United States of America.
- The Kenneth Blum Behavioral and Neurogenetic Institute LLC, Austin, Texas, United States of America.
- Department of Psychology, Faculty of Education and Psychology, Institute of Psychology, Eötvös Loránd University Budapest, Budapest, Hungary.
- Department of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel, Israel.
- Division of Personalized Medicine, Cross-Cultural Research and Educational Institute, San Clemente, California, United States of America.
ORCID-Profile: Kenneth Blum
Förderung
- NINDS NIH HHS
Zitieren
APA
Gold, M. S., Blum, K., Bowirrat, A., Pinhasov, A., Bagchi, D., Dennen, C. A., Thanos, P. K., Hanna, C., Lewandrowski, K. U., Sharafshah, A., Elman, I., & Badgaiyan, R. D. (2024). A historical perspective on clonidine as an alpha-2A receptor agonist in the treatment of addictive behaviors: Focus on opioid dependence. INNOSC Theranostics and Pharmacological Sciences. https://doi.org/10.36922/itps.1918
Vancouver
Gold MS, Blum K, Bowirrat A, Pinhasov A, Bagchi D, Dennen CA, et al. A historical perspective on clonidine as an alpha-2A receptor agonist in the treatment of addictive behaviors: Focus on opioid dependence. INNOSC Theranostics and Pharmacological Sciences. 2024. doi:10.36922/itps.1918
BibTeX
@article{Gold2024,
author = {Gold, Mark S and Blum, Kenneth and Bowirrat, Abdalla and Pinhasov, Albert and Bagchi, Debasis and Dennen, Catherine A and Thanos, Panayotis K and Hanna, Colin and Lewandrowski, Kai-Uwe and Sharafshah, Alireza and Elman, Igor and Badgaiyan, Rajendra D},
title = {A historical perspective on clonidine as an alpha-2A receptor agonist in the treatment of addictive behaviors: Focus on opioid dependence},
journal = {INNOSC Theranostics and Pharmacological Sciences},
year = {2024},
doi = {10.36922/itps.1918}
}
EUVIMED